1. Home
  2. ANL vs BETR Comparison

ANL vs BETR Comparison

Compare ANL & BETR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$12.66

Market Cap

611.1M

Sector

N/A

ML Signal

HOLD

Logo Better Home & Finance Holding Company

BETR

Better Home & Finance Holding Company

HOLD

Current Price

$22.02

Market Cap

518.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
BETR
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
611.1M
518.9M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
ANL
BETR
Price
$12.66
$22.02
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$20.00
$40.00
AVG Volume (30 Days)
249.9K
240.0K
Earning Date
04-10-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$36.02
$55.02
Revenue Next Year
N/A
$65.66
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$12.57
52 Week High
$17.25
$94.06

Technical Indicators

Market Signals
Indicator
ANL
BETR
Relative Strength Index (RSI) 54.70 38.39
Support Level $11.86 N/A
Resistance Level $12.24 $33.00
Average True Range (ATR) 1.14 1.88
MACD 0.31 -0.25
Stochastic Oscillator 68.40 14.03

Price Performance

Historical Comparison
ANL
BETR

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About BETR Better Home & Finance Holding Company

Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.

Share on Social Networks: